{
    "root": "fef562b5-60fa-46d9-a9f8-9caa3c1bc844",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eszopiclone",
    "value": "20250301",
    "ingredients": [
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        }
    ],
    "indications": {
        "text": "eszopiclone tablets indicated treatment insomnia . controlled outpatient sleep laboratory , eszopiclone tablets administered bedtime decreased sleep latency improved sleep maintenance . trials performed support efficacy 6 months duration . final formal assessments sleep latency maintenance performed 4 weeks 6-week study ( adults ) , end 2-week ( elderly ) end 6-month study ( adults ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective dose patient .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ndc 82804-159-90 eszopiclone tablets usp , 1 mg light blue , round , biconvex , film-coated tablets debossed \u2018 h \u2019 one side \u2018 e14 \u2019 side . bottles 60 tablets ndc 82804-159-60 bottles 90 tablets ndc 82804-159-90 store 20\u00b0 25\u00b0 c ( 68\u00b0 77\u00b0 f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 eszopiclonetablet contraindicated patients experienced complex sleep behaviors taking eszopiclone tablets [ error ! hyperlink reference valid . ] . \u2022 eszopiclone tablet contraindicated patients known hypersensitivity eszopiclone . hypersensitivity include anaphylaxis angioedema [ error ! hyperlink reference valid . ] .",
    "indications_original": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance.\u00a0      The clinical trials performed in support of efficacy were up to 6 months in duration.\u00a0 The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications_original": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions_original": "NDC 82804-159-90  Eszopiclone tablets USP, 1 mg are light blue, round, biconvex, film-coated tablets debossed with \u2018H\u2019 on one side and \u2018E14\u2019 on the other side.    Bottles of 60 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 82804-159-60    \n                  Bottles of 90 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 82804-159-90   \n                  \n                    Store at 20\u00b0 to 25\u00b0 C (68\u00b0 to 77\u00b0 F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022\u00a0Eszopiclonetablet is contraindicated in patients who have experienced complex sleep behaviors after taking eszopiclone tablets      [see        \n                     \n                     Error! Hyperlink reference not valid.\n                     \n                        ].      \n                     \n                     \n                       \u2022\u00a0Eszopiclone tablet is contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema      [see        \n                     \n                     Error! Hyperlink reference not valid.\n                     \n                        ].",
    "drug": [
        {
            "name": "Eszopiclone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        }
    ]
}